Jennifer C. Smith-Parker, Director of Insights at BioSpace, spoke with Jason Jones, head of global business development at Cellular Origins, and Alexander Seyf, founder and CEO of Autolomous, in a Denatured podcast episode released on Apr. 9. The discussion focused on how increasing demands in cell and gene therapy manufacturing are leading developers and manufacturers to adopt automation, digitization, robotics, and greater collaboration across the industry.
The conversation is significant as the advanced therapies sector faces growing pressure to scale up production efficiently while maintaining quality standards. Automation and digital tools are seen as essential solutions for meeting these challenges.
Jones shared his perspective as a leader in global business development at Cellular Origins. Seyf contributed insights from his experience founding Autolomous. Both guests discussed the ways that technology is changing how companies operate within the ecosystem of cell and gene therapy manufacturing.
Smith-Parker led the dialogue by exploring current trends shaping advanced therapies production. The episode aimed to highlight practical approaches that organizations can use to address industry bottlenecks through technology-driven strategies.
Listeners were reminded that all views expressed by Jones and Seyf during the podcast are their own opinions and do not represent those of their respective organizations.
